Dermira (NASDAQ:DERM) reached a new 52-week high and low on Friday . The stock traded as low as $7.41 and last traded at $7.35, with a volume of 1363960 shares trading hands. The stock had previously closed at $7.60.
DERM has been the topic of several research reports. Mizuho dropped their price target on Dermira from $43.00 to $39.00 and set a “buy” rating on the stock in a research report on Tuesday, December 12th. Guggenheim restated a “buy” rating and issued a $30.00 price target on shares of Dermira in a research note on Thursday, December 14th. BidaskClub upgraded Dermira from a “hold” rating to a “buy” rating in a research note on Wednesday, December 20th. Zacks Investment Research upgraded Dermira from a “sell” rating to a “hold” rating in a research report on Tuesday, January 9th. Finally, Cantor Fitzgerald set a $45.00 price objective on Dermira and gave the company a “buy” rating in a research report on Monday, January 15th. Four equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Dermira has an average rating of “Buy” and an average target price of $32.71.
The company has a debt-to-equity ratio of 1.87, a current ratio of 5.28 and a quick ratio of 5.28. The stock has a market capitalization of $324.54, a P/E ratio of -1.67 and a beta of 1.52.
In other Dermira news, insider Eugene A. Bauer sold 3,000 shares of the company’s stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $28.55, for a total value of $85,650.00. Following the completion of the sale, the insider now owns 5,802 shares in the company, valued at $165,647.10. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In the last 90 days, insiders sold 4,700 shares of company stock valued at $131,142. Company insiders own 13.30% of the company’s stock.
Institutional investors and hedge funds have recently modified their holdings of the business. AXA increased its position in Dermira by 1.0% in the fourth quarter. AXA now owns 303,474 shares of the biopharmaceutical company’s stock worth $8,440,000 after buying an additional 3,141 shares in the last quarter. Schwab Charles Investment Management Inc. boosted its stake in shares of Dermira by 20.2% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 180,235 shares of the biopharmaceutical company’s stock worth $5,013,000 after acquiring an additional 30,244 shares during the period. Emerald Advisers Inc. PA bought a new position in shares of Dermira in the fourth quarter worth about $14,918,000. Ameriprise Financial Inc. bought a new position in shares of Dermira in the third quarter worth about $2,689,000. Finally, Millennium Management LLC bought a new position in shares of Dermira in the fourth quarter worth about $25,084,000. Institutional investors and hedge funds own 94.93% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Dermira (DERM) Sets New 12-Month High and Low at $7.41” was originally reported by Ticker Report and is the property of of Ticker Report. If you are reading this news story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this news story can be read at https://www.tickerreport.com/banking-finance/3335997/dermira-derm-sets-new-12-month-high-and-low-at-7-41.html.
Dermira, Inc, a biopharmaceutical company, identifies, develops, and commercializes therapies to treat dermatologic diseases. The company's product candidates include Glycopyrronium tosylate, a novel form of an anticholinergic agent that has completed Phase III clinical trial for the treatment of primary axillary hyperhidrosis; Olumacostat glasaretil, a novel small molecule designed to target sebum production, which is in Phase III clinical trial for the treatment of acne vulgaris; and lebrikizumab, a novel humanized monoclonal antibody targeting interleukin 13 that is in Phase 2b development for the treatment of moderate-to-severe atopic dermatitis.
Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.